ArticleJournal of food and drug analysis2025
Fish oil rich in ω-3 fatty acid alleviates long-term high fructose consumption-induced fatty liver and kidney dysfunction in rats.
Article in Journal of food and drug analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excessive fructose intake leads to fatty liver and kidney dysfunction, with associated inflammation and metabolic disturbances. This study evaluated the effects of fish oil rich in ω-3 fatty acid on these conditions in rats fed a high-fructose diet. Male Sprague Dawley rats were divided into three groups: normal diet, high-fructose (HF) diet, and high-fructose diet with 5% fish oil supplementation. The experiment lasted for 21 weeks. Fish oil supplementation significantly reduced blood levels of total cholesterol, triglycerides, and advanced glycation end products (AGEs) in HF-fed rat. It also improved liver function markers and kidney function indicators. Mechanistically, fish oil suppressed fructokinase expression, activated phosphorylated AMP-activated protein kinase (p-AMPK), and decreased peroxisome proliferator-activated receptor (PPAR)-γ expression, reducing triglyceride synthesis-related proteins in the liver. In the kidneys, fish oil supplementation increased p-AMPK and PPARγ, while decreasing inflammatory and oxidative stress markers and fibrosis-related protein α-smooth muscle actin. Histological analysis confirmed that fish oil alleviated liver degeneration and kidney fibrosis. These findings suggest that fish oil not only helps regulate blood lipid levels but also alleviates fructose-induced liver and kidney damage, suggesting its potential as a dietary intervention for metabolic disorders caused by excessive fructose consumption.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.